Checkpoint inhibitors, including programmed cell death protein 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, have remarkably succeeded in clinical trials across various cancer types. This evidence concerns the gene CD274 and cancer.